Clinical trials: Cancer, Digestive System, open to volunteers
Colorectal Cancer, Pancreatic Cancer
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (*1/*28) (heterozygotes) and usual…
- Trial name
- NCT05391126
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Reema A. Patel
Lung Cancer, Esophageal Cancer
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of…
- Trial name
- NCT06019455
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC)…
- Trial name
- NCT06553885
- Testing
- Enfortumab Vedotin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Biliary Tract Cancer
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
This is a single-arm, exploratory, phase II trial to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy combined with adebrelimab and lenvatinib for borderline resectable, locally advanced biliary tract…
- Trial name
- NCT06389500
- Testing
- Adebrelimab, Lenvatinib, Hepatic Arterial Infusion Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Harbin Medical University
Stoma - Ileostomy, High Output Stoma
Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1
The goal of this clinical trial is to evaluate if intensified omeprazole therapy can reduce high-output stoma (HOS) in adults undergoing ileostomy formation surgery.
- Conditions
- Stoma - Ileostomy, High Output Stoma, Colon Cancer, IBD (Inflammatory Bowel Disease)
- Trial name
- STOP-HOS-1 (NCT06917963)
- Testing
- Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM), Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).
- Where
- 2 sites in Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Gdansk
Rectal Cancer
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
The goal of this clinical trial is to learn if neoadjuvant Fruquintinib and Tislelizumab combined with mCapeOX works to treat mid-high pMMR/MSS locally advanced rectal cancer patients compared with CapeOX.
- Trial name
- PKUCH-R09 (NCT06443671)
- Testing
- CapeOX, Fruquintinib and Tislelizumab combined with mCapeOX
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University Cancer Hospital & Institute
HCC - Hepatocellular Carcinoma, Diabetes
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in…
- Trial name
- NCT07557914
- Testing
- Epalrestat, Donafenib + Tislelizumab, HAIC
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Haibo Shao
Immunotherapy, Gastric Cancer (GC)
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
- Conditions
- Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
- Trial name
- NCT07165847
- Testing
- Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Barrett's Esophagus, Esophageal Neoplasm
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2.
- Trial name
- FBE (NCT00288119)
- Testing
- Balloon Capsule Device, Endoscopy
- Where
- 10 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Breast Carcinoma, Cervical Carcinoma
The Ohio State University (OSU) SCREEN Community Program
This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC)…
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
- Trial name
- NCT06666192
- Testing
- Cancer Screening, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 2,067 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Rectal Cancer, Advanced Stage Colorectal Cancer
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
This is a multicenter, cohort, prospective study to evaluate the efficacy and safety of Adebrelimab combined with radiotherapy and chemotherapy as preoperative neoadjuvant therapy for patients with locally advanced rectal cancer.
- Conditions
- Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
- Trial name
- NCT07284992
- Testing
- short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Shandong Provincial Hospital
Colorectal Carcinoma
A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers
This clinical trial evaluates a clinic-wide intervention called Primary Care-Gastrointestinal (GI) Connect for improving follow-up colonoscopy rates in patients at a Federally Qualified Health Center (FQHC) who have an abnormal…
- Trial name
- NCT06568016
- Testing
- Best Practice, Communication Intervention, Coordination
- Where
- 2 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients…
- Trial name
- CCGLC-017 (NCT06954116)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tongji Hospital
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell…
- Conditions
- Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
- Trial name
- PD-L1-PET (NCT06690216)
- Testing
- PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Man Hu
Hepatocellular Carcinoma
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07157306
- Testing
- Gecacitinib Combined With Donafenib and PD-1 Inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1…
- Trial name
- NCT07367516
- Testing
- TQB6411 Injection
- Where
- 30 sites in China
- Volunteers
- 105 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer, Oesophageal Carcinoma
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
This is a Phase 2, open-label, dose optimization/expansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric…
- Trial name
- NCT07692204
- Testing
- SAR445877
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sanofi
Colorectal Cancer, Stomach Cancer
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors…
- Conditions
- Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
- Trial name
- NCT06821048
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Weijia Fang, MD
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.